IDENTIFYING AND CHARACTERIZING METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) POPULATION IN FINLAND

被引：0
|
作者：
Ruotsalainen, J. [1 ]
Korhonen, M. J. [2 ]
Purmonen, T. [2 ]
Joutseno, J. [3 ]
Saavuori, N. [3 ]
机构：
[1] Oriola, Kuopio, Finland
[2] Oriola, Espoo, Finland
[3] Bayer, Espoo, Finland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD161
引用
收藏
页码：S535 / S535
页数：1
相关论文
共 50 条
  • [21] Management of Metastatic Hormone-Sensitive Prostate Cancer
    Brandon Bernard
    Christopher J. Sweeney
    Current Urology Reports, 2015, 16
  • [22] Management of Hormone-Sensitive Metastatic Prostate Cancer
    Agarwal, Neeraj
    Hussain, Maha
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (06) : 1221 - +
  • [23] Update on Metastatic Hormone-Sensitive Prostate Cancer
    Chi, Kim N.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (05) : 277 - 280
  • [24] Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
    Garcia De Herreros, M.
    Jimenez Blasco, N.
    Reig Torras, O.
    Ferrer Mileo, L.
    Aversa, C.
    Garcia-Esteve, S.
    Rodriguez-Carunchio, L.
    Trias Puigsureda, I.
    Padrosa, J.
    Fernandez Manas, L.
    Marin, M.
    Font Pous, A.
    Rodriguez-Vida, A.
    Climent Duran, M. A.
    Cros Costa, S.
    Chirivella Gonzalez, I.
    Figols Gorina, M.
    Mellado Gonzalez, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S992 - S992
  • [25] Genomic profiles and clinical outcomes to distinguish primary from secondary metastatic hormone-sensitive prostate cancer (mHSPC).
    Nizialek, Emily
    Lim, Su Jin
    Wang, Hao
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)
    Henriquez, Ivan
    Malave, Barbara
    Campos, Fernando Lopez
    Hidalgo, Elena Centelles
    Muelas, Rodrigo
    Ferrer, Carlos
    Munoz-Rodriguez, Jesus
    Villamon, Agustina Mendez
    Pascual, Maria Cerrolaza
    Badia, Joan
    Fuertes, Jordi
    Hinojosa-Salas, Percy
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (02): : 706 - 715
  • [27] A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
    Shore, Neal D.
    Morgans, Alicia K.
    Paracha, Noman
    Hodgkinson, Sarah
    Eichinger, Christian
    Millar, Craig
    Chen, Stephanie
    Boegemann, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 324 - 324
  • [28] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [29] Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC).
    Alex, Anitha
    Stenehjem, David D.
    Twardowski, Przemyslaw
    Cheng, Heather H.
    Gill, David Michael
    Buckley, Tyler Howard
    Patel, Shiven B.
    Kessler, Elizabeth Riley
    Chittoria, Namita
    Poudel, Aarati
    Vaishampayan, Ulka N.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease
    Schoen, Martin W.
    Etzioni, Ruth Douglas
    Luo, Suhong
    Candelieri, Danielle
    Fedele, Nicholas
    Baxi, Priya
    Pickett, Carley
    Riekhof, Forest
    Ingram, Kara
    Karunanandaa, Krishny
    Govindan, Srinivas
    Cheranda, Nina
    Knoche, Eric Marshall
    Montgomery, Robert Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345